GLP-1 weight-loss drugs: separating evidence from hype

GLP-1 weight-loss drugs: separating evidence from hype

GLP-1 medications can reduce appetite and food intake, but they do not eliminate hunger. They are associated with gastrointestinal side-effects, nutrient deficiencies and some loss of lean mass, while the evidence for several wider benefits remains incomplete.

The medicines are licensed for people with type 2 diabetes, obesity, or people who are overweight and have weight-related health problems. They are not designed simply for short-term cosmetic weight loss, according to the experts cited here.

What the medicines do to appetite and digestion

GLP-1 medications mimic glucagon-like peptide-1, a hormone involved in appetite regulation. They keep the hormone active for longer than the body’s natural bursts, helping people feel full sooner and suppressing appetite. Hunger eventually returns, however, and the drugs do not completely suppress it. Read the context: What researchers know about poor responses to GLP-1 drugs.

Nausea, constipation, diarrhoea, bloating and vomiting are well-recognised effects, with symptoms tending to occur during dose escalation and improving over time. Smaller meals, adequate fluids and limiting fatty foods may help. Existing reflux or constipation can become worse, according to nutrition expert Federica Amati.

The drugs do not directly make people want to drink less, but reduced food intake and symptoms such as nausea, constipation or reflux can lower overall fluid intake. Hydrating foods and drinks are important because dehydration can worsen reflux and constipation.

Nutrition, muscle and what happens after stopping

Substantially eating less can create a risk of deficiencies in vitamin D, vitamin B12, iron, calcium and protein, particularly when a person’s diet was poor before treatment. The experts recommend paying attention to diet and exercise rather than relying on the injection or tablet alone.

Weight loss includes both fat and lean mass. Current evidence suggests that up to 40% of weight lost with GLP-1 medicine may come from lean mass, which includes bone, muscle and connective tissue. Protein-rich foods and resistance training are therefore important considerations during treatment. Related coverage: Asthma treatment continues deep inside Armenian salt mine despite loss of state support.

Weight regain after stopping is common because appetite suppression ends and hormonal levels return to what they were. Studies cited by the experts indicate that people may regain about 60% of the weight lost; one University of Oxford study found people returned to their original weight within two years.

Claims that remain mixed or unproven

GLP-1 medications do not work for everyone. Between 5% and 20% of people lose less than 5% of their body weight and are classed as non-responders, although the reason for these differences is not yet known.

The evidence that the drugs improve anxiety or depression is described as thin. Some randomised trials have found potential benefits for alcohol use, including fewer heavy-drinking days with semaglutide, but more research is needed for nicotine and other drug dependence.

Bad breath and sulphur-smelling burps have substantial anecdotal reports but no epidemiological evidence. Vomiting, dehydration and slower gastric emptying could contribute to dry mouth or gas from partially digested food, but these explanations are not yet definitive.

Hair, facial changes and possible wider health effects

Hair shedding can occur through telogen effluvium, a stress-response form of hair loss. It is described as reversible as the body adapts, although regrowth speed varies. Rapid loss of facial fat can also reduce support beneath the skin, leaving the face looking looser, more wrinkled or dull.

Researchers are studying benefits beyond weight loss. Findings cited by the experts include a 30% lower likelihood of developing breast cancer in one study, up to a 50% lower likelihood of cancer spreading among some patients, and about a 14% reduction in major adverse cardiovascular events among patients with obesity taking GLP-1 medication. More research is needed to determine how much of these effects comes directly from the medicines rather than from weight loss itself.

Share
Discussion GLP-1 weight-loss drugs: separating evidence from hype

    No comments yet. Start the discussion.

Related Stories